 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population : |
(Universidad de Cantabria) (Universidad de Cantabria) (Cancer Epidemiology Research Group (Madrid)) (Institut d'Investigació Biomèdica de Bellvitge) (Universidad de Oviedo) (Institut Català d'Oncologia) (Instituto de Investigación Sanitaria de Navarra) (Institut Hospital del Mar d'Investigacions Mèdiques) (Universitat Pompeu Fabra) (Cancer Epidemiology Research Group (Madrid)) (Universidad de Cantabria)
| Data: | 2016 |
| Resum: | The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i. e. , menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1. 77 (95% CI, 0. 99 to 3. 17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2. 54, 95% CI, 1. 24 to 5. 22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1. 96, 95% CI = 1. 09 to 3. 53; OR for non ductal cancers = 3. 97, 95% CI = 1. 73 to 9. 05; OR for Erbb2+ cancer = 2. 97, 95% CI: 1. 20 to 7. 32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4. 27, 95% CI = 1. 32 to 13. 84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women). |
| Ajuts: | Ministerio de Ciencia e Innovación PI11/01403 Ministerio de Ciencia e Innovación PI11/01889 Ministerio de Ciencia e Innovación PI11/00226 Ministerio de Ciencia e Innovación PI11/01810 Ministerio de Ciencia e Innovación PI11/02213 Instituto de Salud Carlos III PI08/1770 Instituto de Salud Carlos III PI08/0533 Instituto de Salud Carlos III PI08/1359 Instituto de Salud Carlos III PI09/00773 Instituto de Salud Carlos III PI09/01286 Instituto de Salud Carlos III PI09/01903 Instituto de Salud Carlos III PI09/02078 Instituto de Salud Carlos III PI09/01662 Instituto de Salud Carlos III PI12/00488 Instituto de Salud Carlos III PI12/00265 Instituto de Salud Carlos III PI12/01270 Instituto de Salud Carlos III PI12/00715 Instituto de Salud Carlos III PI12/00150 Ministerio de Economía y Competitividad PI14/01219 Ministerio de Economía y Competitividad RD12/0036/0036 "la Caixa" Foundation 2010ACUP00310 Agència de Gestió d'Ajuts Universitaris i de Recerca 2009-SGR-1489 |
| Nota: | Altres ajuts: Generalitat Valenciana AP_061/10 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Publicat a: | PloS one, Vol. 11 (august 2016) , ISSN 1932-6203 |
